Opko Health Inc (OPK) has been under a strong bear grip, hence the stock is down -0.05% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.18% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.61% in the last 1 week, and is up 2.43% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Opko Health Inc (NYSE:OPK): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.00 and $9.95 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.12. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.11, notching a gain of 1.40% for the day. The total traded volume was 3,415,471 . The stock had closed at $9.97 on the previous day.
The stock has recorded a 20-day Moving Average of 1.95% and the 50-Day Moving Average is 3.33%. Opko Health, Inc. is up 3.91% in the last 3-month period. Year-to-Date the stock performance stands at 0.6%.
Opko Health Inc (OPK) : 4 Wall Street analysts covering Opko Health Inc (OPK) believe that the average level the stock could reach for the short term is $15.25. The maximum price target given is $20 and the minimum target for short term is around $10, hence the standard deviation is calculated at $4.27.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.